Computational and in vitro evaluation of sumac-derived ©Rutan compounds towards Sars-CoV-2 Mpro inhibition
The emergence of the SARS-CoV-2 virus caused the COVID-19 outbreak leading to a global pandemic. Natural substances started being screened for their antiviral activity by computational and <i>in-vitro</i> techniques. Here, we evaluated the anti-SARS-CoV-2 main protease (M<sup>pro</sup>) efficacy of <sup>©</sup>Rutan, which contains five polyphenols (R5, R6, R7, R7', and R8) extracted from sumac <i>Rhus coriaria</i> L. We obtained three fractions after large-scale purification: fraction 1 held R5, fraction 2 consisted of R6, R7 and R7', and fraction 3 held R8. <i>In vitro</i> results showed their anti-M<sup>pro</sup> potential: IC<sub>50</sub> values of R5 and R8 made 42.52 µM and 5.48 µM, respectively. Further, we studied M<sup>pro</sup>-polyphenol interactions by <i>in silico</i> analysis to understand mechanistic extrapolation of Rutan binding nature with M<sup>pro</sup>. We extensively incorporated a series of <i>in silico</i> techniques. Initially, for the docking protocol validation, redocking of the co-crystal ligand GC-376* to the binding pocket of M<sup>pro</sup> was carried out. The representative docked complexes were subjected to long-range 500 ns molecular dynamics simulations. The binding free energy (BFE in kcal/mol) of components were calculated as follows: R8 (-104.636) > R6 (-93.754) > R7' (-92.113) > R5 (-81.115) > R7 (-67.243). <i>In silico</i> results of R5 and R8 correspond with their <i>in vitro</i> outcomes. Furthermore, the per-residue decomposition analysis showed C145, E166, and Q189 residues as the hotspot residues for components contributing to maximum BFE energies. All five components effectively interact with the catalytic pocket of M<sup>pro</sup> and form stable complexes that allow the estimation of their inhibitory activity. Assay kit analyses revealed that Rutan and its components have effective anti-SARS-CoV-2 M<sup>pro</sup> inhibitory activity.
Authors
- Nodir Sh. Berdiev (ORCID: https://orcid.org/0000-0002-3914-2714)
- Yuliya Oshchepkova
- Nurkhodja Mukhamedov
- Muzaffar Kayumov (ORCID: https://orcid.org/0000-0002-4008-2106)
- Jamoliddin Razzokov (ORCID: https://orcid.org/0000-0002-3098-0797)
- Shavkat Salikhov
- Sharafitdin Mirzaakhmedov
- Akmal M. Asrorov (ORCID: https://orcid.org/0000-0001-5700-1061)
- Parthiban Marimuthu (ORCID: https://orcid.org/0000-0003-4960-2160)
- Ansor Yashinov
- Jamolitdin F. Ziyavitdinov (ORCID: https://orcid.org/0000-0001-8337-1218)
Institutions
- Åbo Akademi University (FI)
- Academy of Sciences Republic of Uzbekistan (UZ)
- Chinese Academy of Sciences (CN)
- Tashkent State Technical University named after Islam Karimov (UZ)
- Tashkent Institute of Irrigation and Agricultural Mechanization Engineers (UZ)
- Shanghai Institute of Materia Medica (CN)
- National University of Uzbekistan (UZ)
- Saveetha University (IN)
Publication Details
- Journal
- Frontiers in Pharmacology
- Published
- 2025-02-04
- DOI
- https://doi.org/10.3389/fphar.2025.1518463
- Citations
- 3
- Primary Topic
- Medicinal Plant Research
- Type
- article
- Field-Weighted Citation Impact
- 5.25
Funders
- Juhani Ahon Lääketieteen Tutkimussäätiö
- China Scholarship Council
- Biocenter Finland